This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Aneurysm of Aorta in Diseases Classified Elsewhere달리 분류된 질환에서의 대동맥의 동맥류

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: I79.0 (aneurysm of aorta in diseases classified elsewhere) | Special Copayment Reduction: V192 (special copayment reduction for heart disease: 5% copayment for up to 30 days from the registration date)
B. Coding rulesI79.0 is a manifestation code, and the code for the underlying causative disease (A52.01, etc.) must always be recorded first. For A52.01 (syphilitic aneurysm of aorta), coding A52.01 alone takes precedence over I79.0.
C. Main causative diseasesSyphilitic aortitis (A52.01), tuberculous aortitis, mycotic aortic aneurysm of bacteremic origin, Takayasu arteritis, giant cell arteritis, Behçet disease, Salmonella infection, etc.
1. HistorySyphilitic aortic aneurysm was a major aortic disease in the pre-antibiotic era. It declined sharply after the introduction of penicillin (1943), but cardiovascular syphilis is now being re-examined amid the resurgence of syphilis.
2. CausesCausative diseases include bacteria and bacteremia such as syphilis (Treponema pallidum), Mycobacterium tuberculosis, Salmonella and staphylococci, Takayasu and giant cell arteritis, Behçet disease and rheumatoid arteritis.
3. GeneticsGenetic predisposition is not a direct cause of syphilitic and infection-related aortic aneurysms, but HLA-B52 (Takayasu), HLA-B51 (Behçet), PTPN22 variants (rheumatoid) and others are involved in susceptibility to immune vasculitis.
4. General epidemiologySyphilitic aortic aneurysms accounted for 5–10% of all aortic aneurysms in the pre-antibiotic era but now account for less than 1%. Mycotic aneurysms are rare, at 0.5–1.3% of all aortic aneurysms.
5. PathophysiologySyphilis: obliterative endarteritis of the vasa vasorum → ischemic necrosis of the aortic media → destruction of elastic fibers → aortic dilatation. Tuberculosis/infection: direct invasion from surrounding tissue.
6. SymptomsChest pain, back pain, dysphagia (esophageal compression), hoarseness (recurrent laryngeal nerve compression), dyspnea, cough, symptoms of aortic regurgitation. On rupture, severe chest pain and shock.
7. SignsAortic regurgitation murmur (diastolic murmur), widened pulse pressure, mediastinal widening on chest X-ray, irregular aortic wall thickening and periaortic inflammation on CT, positive serum RPR/TPPA (syphilis).
8. ScreeningTargeted screening according to the causative disease. Syphilis: RPR and TPPA serology. Immune vasculitis: inflammatory markers (ESR, CRP), autoantibody panel. Tuberculosis-endemic areas: IGRA and chest CT.
9. DiagnosisCTA (aortic structure assessment), PET-CT (vasculitis activity assessment), TEE (aortic valve and root), serum syphilis tests (RPR + TPPA confirmatory test), tissue biopsy (pathology: plasma cell infiltration, identification of spirochetes).
10. TreatmentTreat the causative disease first: syphilis — benzathine penicillin G 2.4MU IM once weekly for 3 weeks. Tuberculosis — four-drug antituberculosis regimen. Infectious — broad-spectrum antibiotics. Aortic aneurysm surgery (EVAR/open): when size criteria are met or there is a risk of rupture.
11. PrognosisMycotic aortic aneurysm: operative mortality 20–40%, 5-year survival 30–50%. Syphilitic aortic aneurysm: improved prognosis with surgery after penicillin treatment. Mortality is extremely high with untreated rupture.
12. PreventionEarly diagnosis and treatment of syphilis (screening tests), infection prevention (antiseptic sexual hygiene), tuberculosis prevention (BCG vaccination, LTBI treatment), aggressive immunosuppressive treatment of vasculitis, regular aortic imaging follow-up.
13. ReferencesSyphilitic Cardiac and Vascular Disease: A Comprehensive Review (PMID 41198090) and 9 other papers

1. History

Aortic aneurysm in diseases classified elsewhere (ICD-10 I79.0) is not an independent disease entity in itself but a coding concept denoting a clinical phenotype in which various underlying diseases, such as syphilis, tuberculosis, infection and vasculitis, commonly invade the aortic wall and form an aneurysm. Historically the most important cause is cardiovascular syphilis, which in the pre-antibiotic era was one of the main causes of all aortic aneurysms.

Syphilis is a sexually transmitted infection caused by Treponema pallidum; since it was first recorded in Europe in 1495, it was pandemic worldwide for hundreds of years. Aortitis and aortic aneurysm as cardiovascular complications of tertiary syphilis were systematically described by pathologists in the late 19th and early 20th centuries. William Osler (1885), Hektoen (early 1900s) and others described the clinical and pathological features of syphilitic aortitis, confirming in particular that fusiform aneurysms involving the ascending aorta and aortic arch are typical.

After Alexander Fleming's discovery of penicillin in 1928 and its clinical application in 1943 made syphilis treatable, cardiovascular syphilis declined sharply. However, since the late 20th century syphilis has been resurging worldwide due to changing patterns of sexually transmitted infections, co-epidemics with HIV infection and antibiotic resistance, and more than 200,000 new cases of syphilis were reported in the United States alone in 2022. As a result, cardiovascular syphilis and syphilitic aortic aneurysm are again drawing attention in modern clinical practice. Meanwhile, tuberculous aortic aneurysm, mycotic aortic aneurysm and vasculitis-related aortic aneurysm are also recognized as rare but important clinical entities.

In terms of ICD coding, I79.0 is used by recording the code for the preceding (causative) disease first and then adding it as a manifestation code; for syphilitic aortic aneurysm, the ICD rule is to use A52.01 (Syphilitic aneurysm of aorta) as the primary code, and I79.0, which falls under a Type 1 exclusion note, is not used together with A52.01. Therefore, in clinical practice, the cases to which I79.0 actually applies are mainly aortic aneurysms caused by diseases other than syphilis, such as tuberculosis, fungal infection and vasculitis.


2. Causes

I79.0 is a code that covers aortic aneurysms formed secondarily by various underlying diseases. The clinically most important and historically significant cause is tertiary syphilis, in which cardiovascular syphilis manifests in untreated or inadequately treated patients 10–30 years after infection. Cardiovascular syphilis develops in about 10% of people infected with syphilis, and aortic aneurysm is observed in about 71% of these. Syphilitic aortitis mainly involves the ascending aorta, forming a fusiform aneurysm, and can at the same time cause aortic valve regurgitation and coronary ostial stenosis, forming the cardiovascular syphilis triad.

Tuberculous aortitis is an aortic infection caused by Mycobacterium tuberculosis, arising mainly through contiguous spread from adjacent mediastinal lymph nodes or pulmonary tuberculosis lesions. Tuberculous aortic aneurysm is rare, but it should not be overlooked clinically in tuberculosis-endemic areas. Pathologically, granuloma formation is characteristic, and it can be difficult to distinguish from Takayasu arteritis.

Mycotic aortic aneurysm, despite the term, includes infectious aortic aneurysms of bacterial origin. It arises when the aortic intima becomes infected through bacteremia (hematogenous seeding) or by direct spread from an adjacent infectious focus. The main causative organisms are Salmonella (Salmonella spp.), Staphylococcus aureus, Escherichia coli, Klebsiella (Klebsiella pneumoniae) and, rarely, fungi (Candida, Aspergillus). Salmonella in particular tends to infect atherosclerotic lesions of the abdominal aorta and cause mycotic aortic aneurysms.

Aortic aneurysm can also occur in immune vasculitis. Takayasu arteritis is a granulomatous vasculitis involving the aorta and large vessels that occurs mainly in young women; aortic stenosis is characteristic, but aortic aneurysm accompanies it in some cases. Giant cell arteritis occurs mainly in people aged 50 and over and increases the risk of thoracic aortic aneurysm. Behçet disease is characterized by oral ulcers, uveitis and genital ulcers, and large vessel involvement leads to aortic aneurysm and thrombus formation. Rheumatoid arthritis, ankylosing spondylitis and relapsing polychondritis can also be accompanied by aortic involvement.


3. Genetics

The genetic background of aortic aneurysm in diseases classified elsewhere differs by causative disease. In infectious causes (syphilis, tuberculosis, bacteria), direct genetic predisposition does not determine onset, but genes involved in the efficiency of the immune response can affect severity. Toll-like receptor (TLR) gene polymorphisms regulate the strength of the host immune response to bacterial infection, and studies suggest they may affect vulnerability to infectious aortic aneurysm.

Genetic predisposition is better characterized in immune vasculitis. In Takayasu arteritis, HLA-B52 is the most strongly associated genetic marker, and the prevalence of the HLA-B*52:01 allele is markedly high in Asian patients in Japan, Korea, India and elsewhere. GWAS have reported that loci such as IL12B (interleukin-12B), FCGR2A/3A and MLX are associated with susceptibility to Takayasu arteritis. In giant cell arteritis, the HLA-DRB1*04 allele is strongly associated, and PTPN22 and IL17A variants are also involved. In Behçet disease, HLA-B51 (especially HLA-B*51:01) is the most important genetic risk factor, consistent with its high prevalence in East Asian and Middle Eastern populations. Recent GWAS have shown that genes in immune regulatory pathways, such as IL10, IL23R and ERAP1, are involved in susceptibility to Behçet disease.

Gene profiling in immune vasculitis therefore plays an important role in differential diagnosis, understanding of the disease and development of targeted therapies. Meanwhile, in patients with an underlying genetic predisposition (Marfan, Loeys-Dietz, etc.), accompanying infection or vasculitis can further accelerate aortic complications, so an evaluation that considers these combined factors is needed.


4. General epidemiology

Aortic aneurysm in diseases classified elsewhere (I79.0) is rare overall, but its epidemiology differs by causative disease. Syphilitic aortic aneurysm accounted for a considerable share in the pre-antibiotic era but has now fallen to less than 1% of all aortic aneurysms. However, with the worldwide resurgence of syphilis, reports related to cardiovascular syphilis are increasing. According to the US CDC, new syphilis cases in the United States reached 207,255 in 2022, the highest level on record, and cardiovascular syphilis occurs more often in people with HIV infection.

Mycotic aortic aneurysm accounts for about 0.5–1.3% of all aortic aneurysms, with a higher incidence in acquired immunodeficiency states (diabetes, immunosuppressant therapy, HIV, hemodialysis). It most often involves the abdominal aorta (about 70%), with thoracic aortic involvement in about 20%. Mortality is high, with 30-day mortality around treatment reported at 20–40%. Tuberculous aortic aneurysm accounts for about 0.3–1% of all aortic aneurysms and occurs more frequently in tuberculosis-endemic countries (Asia, Africa). In Korea, too, tuberculosis incidence is still relatively high among OECD countries, so it needs clinical consideration.

Takayasu arteritis has a worldwide prevalence of 0.4–2.6 per million and is more common in women in Asia, the Middle East and South America. The mean age at onset is 15–40 years. Giant cell arteritis occurs in people aged 50 and over, with a high prevalence among those of Northern European descent (15–30 per million). The risk of thoracic aortic aneurysm is increased about 17-fold compared with the general population. Behçet disease has a high prevalence in Silk Road regions (East Asia, the Middle East, the Mediterranean) and is relatively common in Korea, Japan, Iran and elsewhere.


5. Pathophysiology

The pathophysiology of syphilitic aortitis begins when Treponema pallidum spreads hematogenously after initial infection and invades the vasa vasorum of the aortic adventitia. The spirochetes induce an inflammatory response in the intima of the vasa vasorum, causing obliterative endarteritis, which narrows the lumen of the vasa vasorum and reduces blood flow. As a result, ischemic necrosis develops in the outer two-thirds of the aortic media (the part nourished by the vasa vasorum), and elastic fibers and smooth muscle cells are destroyed.

When the structural support of the aortic media is lost through destruction of elastic fibers and collagen remodeling, the aorta can no longer withstand the pressure load and gradually dilates. This process is especially prominent in the ascending aorta and aortic arch, resulting in a fusiform thoracic aortic aneurysm. Characteristic pathological findings are lymphocytic and plasma cell infiltration of the adventitia, fragmentation of elastic fibers in the media, and "tree-bark" wrinkling of the intima (tree-bark appearance). Syphilitic aortitis can also extend to the aortic valve annulus, causing aortic regurgitation, and when the inflammation involves the coronary ostia, coronary ostial stenosis develops.

The pathophysiology of mycotic aortic aneurysm involves bacteria in a bacteremic state lodging at sites of minor damage to the aortic intima (especially atherosclerotic lesions), or direct spread from adjacent lymph node or spinal infection. As the bacteria proliferate in the aortic wall, they secrete proteolytic enzymes that rapidly destroy the elastic fibers and collagen of the aortic wall, and the local inflammatory response further weakens the wall. Mycotic aortic aneurysms grow very quickly and can rupture within days to weeks, making them an emergency. In tuberculous aortic aneurysm, Mycobacterium tuberculosis spreads directly to the aortic adventitia from the adjacent mediastinum, pleura or spine, or hematogenously, causing granuloma formation and destruction of the aortic wall.

In immune vasculitis, an autoimmune response attacks the aortic wall. In Takayasu arteritis, CD4+ T cells, NK cells and macrophages cause inflammation in the adventitia of large vessels and form granulomas, leading to intimal hyperplasia and medial fibrosis. Giant cell arteritis is characterized by T cell and giant cell infiltration progressing from the adventitia to the intima, with activation of Th1/Th17 immune pathways centered on IL-6 and IFN-γ. In these vasculitides, too, the media of the aortic wall is destroyed and aneurysmal dilatation develops.


6. Symptoms

Aortic aneurysm in diseases classified elsewhere often mainly involves the ascending or thoracic aorta (especially in syphilis, Takayasu and giant cell arteritis), and the resulting symptoms are characteristic. In many cases the aneurysm itself is asymptomatic, with symptoms of the underlying disease to the fore, or it is found incidentally on imaging.

When symptoms are present, chest pain or back pain is the most common, and various symptoms arise as the aneurysm enlarges and compresses surrounding structures. As an ascending aortic or aortic arch aneurysm enlarges, dysphagia (esophageal compression), hoarseness (compression of the left recurrent laryngeal nerve) and superior vena cava syndrome (facial swelling, arm swelling and jugular venous distension when the superior vena cava is compressed) may appear. Compression of the bronchi or lungs causes cough, dyspnea and recurrent pneumonia.

In syphilitic aortitis, as aortic regurgitation worsens, heart failure symptoms such as exertional dyspnea, nocturnal orthopnea and leg edema appear. As coronary ostial stenosis progresses, an angina or acute coronary syndrome picture may appear. In mycotic aortic aneurysm, local pain occurs together with symptoms of systemic infection such as fever, chills and weight loss, and rupture from rapid growth presents with sudden, severe thoracoabdominal pain and hemodynamic shock. In tuberculous aortitis, typical symptoms of pulmonary tuberculosis (cough, hemoptysis, sweating, weight loss, fever) may be present.


7. Signs

Physical examination findings differ with the underlying disease and the size and location of the aneurysm. In syphilitic aortitis with advanced aortic regurgitation, classic signs of aortic regurgitation are observed, such as a diastolic murmur (high-pitched decrescendo diastolic murmur at the left sternal border), wide pulse pressure, a strong bounding pulse (Corrigan's pulse, water-hammer pulse), head bobbing (de Musset's sign) and fundal pulsation (Quincke's sign). On cardiac auscultation, the aortic regurgitation murmur is best heard at the lower left sternal border.

When mediastinal widening or dilatation of the aortic shadow is seen on chest X-ray, aortic aneurysm is suspected. The sensitivity of chest X-ray is low, but aortic calcification helps define the aortic contour. Mycotic aortic aneurysm is accompanied by high fever (38.5°C or higher), local tenderness and signs of sepsis (tachycardia, hypotension), and the causative organism may grow in blood cultures. Blood tests show marked elevation of CRP and ESR.

On syphilis serology, a positive RPR (Rapid Plasma Reagin) and a positive confirmatory TPPA (Treponema pallidum particle agglutination) are central to the diagnosis of cardiovascular syphilis. A high RPR titer suggests active infection, but because TPPA remains positive for life even after past treatment, the trend of the RPR titer is important in judging activity. In Takayasu arteritis, elevated ESR and CRP and, in some cases, leukocytosis are observed. Segmental large vessel stenosis and some aneurysmal lesions on angiography or CTA are characteristic.


8. Screening

The key to screening for aortic aneurysm in diseases classified elsewhere is that it takes place within the management framework of the causative disease. For syphilis screening, RPR screening is recommended in groups at high risk of active sexually transmitted infection (multiple partners, people with HIV infection, men who have sex with men), pregnant women, before transfusion and so on. If positive, it is confirmed with TPPA, and when tertiary syphilis or neurosyphilis/cardiovascular syphilis is suspected, chest CT and echocardiography are added.

In groups at high risk of tuberculosis, latent or active tuberculosis is screened for with IGRA (Interferon-Gamma Release Assay) or the tuberculin skin test (TST), chest X-ray and sputum tests, and when tuberculous aortic aneurysm is suspected, chest-abdominal CTA is performed. To screen for immune vasculitis, ESR, CRP, complete blood count and an autoantibody panel (ANA, ANCA, RF) are performed, and when Takayasu arteritis or giant cell arteritis is suspected, the aorta and branch vessels are evaluated with ultrasound or MRA. In groups at high risk of infection (diabetes, organ transplantation, HIV, hemodialysis), abdominal pain with fever calls for actively ruling out mycotic aortic aneurysm, and CT or 18F-FDG PET-CT is useful for diagnosis.

In the Korean setting, the baseline prevalence of syphilis is not high, but with the recent rise in sexually transmitted infections, vigilance for cardiovascular syphilis is needed. Tuberculosis incidence is relatively high among OECD countries, so the possibility of aortic involvement should always be kept in mind in patients with thoracic tuberculosis. Takayasu arteritis is relatively more common in East Asian women, so young women should be actively evaluated when there is a difference in arm blood pressure, pulse deficit or a vascular bruit on auscultation.


9. Diagnosis

Diagnosis of aortic aneurysm in diseases classified elsewhere rests on two pillars: evaluation of aortic structure and confirmation of the underlying causative disease. CT angiography (CTA) is the standard method for most precisely evaluating the size, location and shape of the aneurysm and its relationship to surrounding structures. In syphilitic aortic aneurysm, CTA shows fusiform dilatation of the ascending aorta, irregular intimal calcification and wall thickening. In mycotic aortic aneurysm, rapid growth, inflammation of surrounding soft tissue, pseudoaneurysm formation and periaortic gas bubbles are characteristic.

18F-FDG PET-CT is especially useful for evaluating vasculitis activity. In Takayasu arteritis, giant cell arteritis and infectious aortitis, areas of increased FDG uptake indicate inflammatory, active vessel segments. MRA can evaluate aortic morphology without radiation exposure, making it suitable for follow-up of vasculitis, and it can be used instead of CTA with iodinated contrast in patients with reduced renal function. Transesophageal echocardiography (TEE) evaluates the ascending aorta, aortic valve and coronary ostia at high resolution and is useful for assessing syphilitic aortic regurgitation and coronary ostial stenosis.

Syphilis serology combines RPR (nonspecific test) and TPPA (specific confirmatory test). In tertiary cardiovascular syphilis, RPR shows a moderate titer and TPPA is positive. CSF testing (CSF-VDRL, cell count, protein) is recommended to rule out accompanying neurosyphilis. Histopathological examination of aortic wall tissue obtained at surgery or biopsy identifies plasma cell and lymphocyte infiltration (syphilis), granuloma formation (tuberculosis, Takayasu) and monocyte and neutrophil infiltration (bacterial infection). Treponema pallidum in tissue can be identified by silver staining (Warthin-Starry stain) or PCR.


10. Treatment

Treatment of aortic aneurysm in diseases classified elsewhere combines treatment of the causative disease as the top priority, followed by surgical intervention according to aneurysm size and risk. In syphilitic aortic aneurysm, the standard antimicrobial treatment is benzathine penicillin G 2.4 million units (MU) intramuscularly (IM) once weekly for 3 consecutive weeks. With penicillin allergy, doxycycline 100mg twice daily for 28 days is used as an alternative. After antimicrobial treatment, the RPR titer is followed at 3, 6, 12 and 24 months to confirm treatment response (a fourfold or greater decrease in titer).

Surgical treatment of the aneurysm is decided considering size criteria (generally a thoracic aorta of 5.5cm or more, or growth of 1cm or more per year), rupture risk and the presence of symptoms. In syphilitic aortic aneurysm, surgery is recommended after aortic inflammation has stabilized following antimicrobial treatment. Depending on anatomical conditions, the surgical method chosen is open surgical repair (ascending aortic replacement, the Bentall procedure including composite aortic valve replacement, etc.) or an endovascular stent graft (EVAR/TEVAR). In syphilitic aortic aneurysm with severe aortic regurgitation, aortic valve replacement is performed at the same time.

Mycotic aortic aneurysm requires immediate broad-spectrum antibiotic treatment (antibiotics started empirically after blood cultures, before the causative organism is identified). According to the main organism, fluoroquinolones or third-generation cephalosporins are used for Salmonella, and vancomycin (when MRSA is suspected) or oxacillin for Staphylococcus aureus. Surgical treatment consists of aneurysm resection and vascular graft reconstruction (in situ graft or extra-anatomic bypass surgery), and in high-risk patients EVAR, accepting the risk of infection, can be an alternative. In tuberculous aortic aneurysm, it is recommended to give standard four-drug antituberculosis therapy (HRZE) first and perform surgery afterward.

In immune vasculitis, glucocorticoids such as prednisolone are first-line treatment to suppress inflammation. In Takayasu arteritis, initial high-dose steroids (prednisolone 1mg/kg/day) are given, and with an insufficient response or relapse, tocilizumab (an IL-6 receptor inhibitor), methotrexate or azathioprine is added. In giant cell arteritis, too, tocilizumab is combined with high-dose steroids to facilitate steroid tapering. Surgery is performed when the aneurysm meets surgical criteria while the vasculitis is maintained in remission; surgery during active vasculitis carries a high risk of complications.


11. Prognosis

The prognosis of aortic aneurysm in diseases classified elsewhere differs greatly by underlying disease, aneurysm size, timing of diagnosis and timeliness of treatment. Mycotic aortic aneurysm has the worst prognosis, with a perioperative 30-day mortality reported at about 20–40%. Even among survivors the 5-year survival rate is only 30–50%, with recurrent infection, aortic reoperation and septic complications as the main causes of death. When managed with conservative treatment alone (antibiotics only), the risk of rupture is extremely high and short-term survival is markedly poor.

The prognosis of syphilitic aortic aneurysm improves when surgery is combined with benzathine penicillin treatment. The 10-year survival of unruptured syphilitic aortic aneurysm before treatment tends to be improving, but the severity of aortic regurgitation and the presence of coronary involvement determine the long-term prognosis. With severe aortic regurgitation and heart failure, the prognosis deteriorates rapidly if untreated. Tuberculous aortic aneurysm has a good prognosis when antituberculosis therapy is combined with surgery, but the risk of rupture is high if diagnosis is delayed.

In aortic aneurysm related to immune vasculitis, controlling the activity of the underlying vasculitis is key to halting aneurysm progression. In Takayasu arteritis, aneurysm growth is suppressed in patients who maintain clinical remission, whereas patients with repeated relapses have a high risk of aortic complications. The 15-year survival of patients with Takayasu arteritis is about 80–90%, and thoracic aortic aneurysm related to giant cell arteritis shows a surgical risk similar to that of thoracic aortic aneurysm in general. In Behçet disease, large vessel involvement carries a poor prognosis, and repeated surgery is often needed.

Common to all causes, early diagnosis and appropriate treatment of the cause are emphasized as the most important factors determining prognosis. Monitoring the growth rate of the aneurysm and optimizing the timing of surgery through regular aortic imaging follow-up (CTA or MRA, at 6–12-month intervals) is essential.


12. Prevention

Prevention of aortic aneurysm in diseases classified elsewhere depends on prevention and early treatment of the causative disease. Key to syphilis prevention are consistent use of barrier contraception including condoms, fewer partners, screening for sexually transmitted infections (RPR testing at least once a year in high-risk groups) and prompt treatment when early syphilis is diagnosed (a single dose of benzathine penicillin 2.4MU). Particularly in people with HIV infection, early detection and treatment of syphilis can prevent progression to cardiovascular syphilis. Contact tracing and preventive treatment of sexual contacts of syphilis patients are effective in interrupting transmission.

In tuberculosis prevention, BCG vaccination, early diagnosis and isolation of patients with active tuberculosis, and treatment of latent tuberculosis infection (LTBI) (isoniazid for 9 months or rifampin for 4 months) are the foundation for preventing tuberculous aortic aneurysm. When a mediastinal abnormality is found during chest imaging follow-up in a tuberculosis-endemic area, tests to rule out tuberculous aortic involvement are performed. To prevent infectious (mycotic) aortic aneurysm, thorough management of diabetes and immunosuppressed states, early treatment of bacteremia and adherence to endocarditis prevention guidelines are important. To prevent Salmonella infection, food hygiene and proper cooking are needed.

In immune vasculitis, controlling disease activity through immunosuppressive treatment is key to preventing aortic complications. Patients with Takayasu arteritis and giant cell arteritis maintain vasculitis remission with aggressive treatment, including biologics, and the aorta is followed with regular PET-CT or MRA. Blood pressure control (systolic target <130mmHg), lipid-lowering therapy (statins) and smoking cessation contribute to additional risk reduction in aortic aneurysm of all causes. In patients diagnosed with a causative disease, regular aortic imaging follow-up enables early detection of aneurysms and decisions on the timing of preventive surgery.


13. References

  1. Esbenshade AJ, Bhattacharya D, Baughn AD, et al. Syphilitic Cardiac and Vascular Disease: A Comprehensive Review. Cardiology in Review. 2025;33(1):1-12. PMID: 41198090.

  2. Dominguez-Castellano A, Reguera-Iglesias JM, Corzo-Delgado JE, et al. Syphilitic Aortitis. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. PMID: 35550616.

  3. Erbel R, Aboyans V, Boileau C, et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases. Eur Heart J. 2014;35(41):2873-2926. DOI: 10.1093/eurheartj/ehu281. PMID: 25173340.

  4. Lima GBDS, Cury JL, Ribeiro AM, et al. Contained rupture of an aortic arch aneurysm in a patient with syphilitic aortitis: a case report. BMC Cardiovasc Disord. 2022;22(1):39. PMC: PMC8759583.

  5. Minhajuddin M, Minhajuddin SM. Syphilitic Aortic Aneurysm: A Rare Entity in the Era of Antibiotics. Cureus. 2021;13(3):e13734. PMC: PMC8012739.

  6. Meng X, Liu S, Lai H, et al. Syphilitic aortic aneurysm with a pulmonary lesion: a case report and literature view. J Cardiothorac Surg. 2016;11(1):139. PMC: PMC5053956.

  7. Sörelius K, Mani K, Björck M, et al. Mycotic Thoracic Aortic Aneurysm: Epidemiology, Pathophysiology, Diagnosis, and Management. Semin Vasc Surg. 2022;35(4):449-462. PMC: PMC9632233.

  8. Gornik HL, Creager MA. Aortitis. Circulation. 2008;117(23):3039-3051. DOI: 10.1161/CIRCULATIONAHA.107.760686. PMID: 18541754.

  9. Keser G, Direskeneli H, Aksu K. Management of Takayasu arteritis: a systematic review. Rheumatology (Oxford). 2014;53(5):793-801. DOI: 10.1093/rheumatology/ket320. PMID: 24026308.

  10. Wiesmann F, Bhatt DL, Stone GW, et al. Mycotic Aortic Aneurysm Secondary to Salmonella enterica Infection: A Case Report and Treatment Approach. JACC Case Rep. 2024. PMC: PMC11024485.